


Versicolor-Based Vaginal Gel

Amal Snoussi, MD – Hospital Practitioner in Gynecology and Obstetrics – Romorantin-Lanthenay Hospital Center, France

BACKGROUND & OBJECTIVE



Context: Persistent HPV infection following CIN2+ excisional treatment (conization) is common. Excision removes the lesion but not always the underlying viral infection, posing a risk for recurrence.



Objective: Evaluation of HPV clearance rates at 6 months post-excisional treatment in patients using Papilocare® (*Coriolus versicolor*-based gel) compared to standard care (Control) in real-life setting.

METHODS



FOLLOW-UP TIMELINE: Baseline → 6 Months (HPV Testing)



Retrospective, single-center study.

Inclusion Criteria: Confirmed CIN2/CIN3/CIN2+3, positive baseline hrHPV, HPV test result available at 6 months.

RESULTS

Group	Patients (n)	Clearance (%)	Persistence (%)
Papilocare	60	73.3%	26.7%
Control	33	69.7%	30.3%

Note: No statistically significant difference in clearance rates ($p = 0.89$).



Vaginal gel well tolerated –
No treatment-related adverse events reported

DISCUSSION

- High HPV clearance rates were observed at 6 months after excisional treatment (conization) across the entire cohort.
- No **additional benefit** of Papilocare® was observed in promoting HPV clearance compared to the control group in this study.
- Limitations include the retrospective design, small sample size, potential selection bias, and single-center setting.

CONCLUSION

Excisional treatment for CIN2+ leads to high HPV clearance rates at 6 months regardless of Papilocare® use. Further research with larger, prospective studies is